1,720,978 research outputs found
Correlation between the tumoral Targeting of 111In-labeled Humanized 3S193 Monoclonal Antibody on SPECT and the Tumoral Uptake of Fluorodeoxyglucose on PET in small cell lung cancer.
No full textNovel PET Imaging Techniques in the Management of Hematologic Malignancies
No full textHematology is probably the most relevant application field of PET since the widespread adoption of PET in the 1990s. Currently, the use of PET is indispensable in the natural history of almost all onco-hematologic diseases. With the advent of innovative therapies, such as CAR-T, the use of PET has gained further clinical diagnostic value. Significant innovations are also seen in the therapeutic and theranostic fields, and greater developments are anticipated in the future. Ultimately, the clinical applications of PET in onco-hematology likely represent the largest portion of the daily workload in most PET centers, and clinical hematologists have long relied on these molecular imaging techniques.
In the current issue, we have asked leading international experts in onco-hematology imaging and therapy to contribute their insights on the state-of-the-art applications of PET and therapeutic techniques in major hematologic diseases and to provide perspectives on potential future diagnostic and therapeutic applications in this field. Despite the necessarily limited space, we have endeavored to cover all relevant topics. Contributions have come from top experts in both established application fields, which constitute the daily practice, such as in the article “[18F]FDG PET Imaging for Therapy Assessment in Hodgkin and Non-Hodgkin Lymphomas" by the group led by Prof Roland Hustinx, and in new diagnostic possibilities in the article "New PET Tracers for Lymphoma." Therapeutic applications also have an important focus: the past and future of therapeutic applications in lymphomas have been brightly reported by a leading expert, such as Prof Elba Etchebehere, and collaborators. We have given ample space to current and future diagnostic applications in Multiple Myeloma, including a comparison of PET imaging with whole-body MR imaging. This issue would not be complete without mentioning the contribution of new PET machines with long axial fields of view, with an interesting article by Prof Nardo from the University of California, Davis, or the applications of PET in Chimeric Antigen Receptor T-Cell Trafficking, radiomics, or new quantitative PET methods in onco-hematology.
In conclusion, the use of PET and radioligand therapies in onco-hematology constitutes the present of our daily activities, but innovations in new theranostic radiopharmaceuticals and technological advancements ensure an increasingly bright future and an ever-greater significance of molecular imaging in onco-hematology.
We want to thank all the authors and collaborators for their spontaneous, free, and enthusiastic contributions to this project, which will undoubtedly be a valuable resource for both clinicians and imaging experts
Targeting of Radiolabeled Monoclonal Antibodies in Small Cell Lung Cancer: Correlation between the Targeting of 111In-labeled Humanized 3S193 Monoclonal Antibody on SPECT and the Tumoral Uptake of Fluorodeoxyglucose on PET.
No full textUtilizzo dell’anticorpo chimerico marcato con 124-I nella diagnosi pre-chirurgica del tumore renale a cellule chiare in pazienti con masse renali operabili.
No full textThe value of Gamma Camera and Computed Tomography data set Coregistration to assess the Lewis Y antigen targeting in Small Cell Lung Cancer by 111Indium - labelled Humanized Monoclonal Antibody 3S193.
No full textCorrelation between the tumoral Targeting of 111In-labeled Humanized 3S193 Monoclonal Antibody on SPECT and the Tumoral Uptake of Fluorodeoxyglucose on PET in small cell lung cancer
No full textPilot study of iodine-124 labeled chimeric G250 (124I-cG250) in the presurgical diagnosis of clear cell-type renal carcinoma in patients with operable renal masses.
No full textTargeting Lewis Y (LeY) in small cell lung cancer (SCLC) with a humanized monoclonal antibody, hu3S193: A pilot trial testing two dose levels.
No full textPharmacokinetic Modeling and Optimization of Omburtamab (8H9) Delivered Through Cerebrospinal Fluid: Accompanying MATLAB Code
No full textThis is the accompanying code for the article:
Yerrabelli, R.S., He, P., Fung, E.K., Kramer, K., Zanzonico, P.B., Humm, J.L., Guo, H., Pandit-Taskar, N., Larson, S.M., & Cheung, N.V (2021). IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. European journal of nuclear medicine and molecular imaging, 48(4), 1166-1177. doi:10.1007/s00259-020-05050-z. PMID: 33047248. PMCID: PMC8279045
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for Radionuclide Imaging of Phaeochromocytoma and Paraganglioma
No full textPurpose: Diverse radionuclide imaging techniques are available for the diagnosis, staging, and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to detect and localise the disease, these imaging approaches variably characterise these tumours at the cellular and molecular levels and can guide therapy. Here we present updated guidelines jointly approved by the EANM and SNMMI for assisting nuclear medicine practitioners in not only the selection and performance of currently available single-photon emission computed tomography and positron emission tomography procedures, but also the interpretation and reporting of the results.
Methods: Guidelines from related fields and relevant literature have been considered in consultation with leading experts involved in the management of PPGL. The provided information should be applied according to local laws and regulations as well as the availability of various radiopharmaceuticals.
Conclusion: Since the European Association of Nuclear Medicine 2012 guidelines, the excellent results obtained with gallium-68 (68Ga)-labelled somatostatin analogues (SSAs) in recent years have simplified the imaging approach for PPGL patients that can also be used for selecting patients for peptide receptor radionuclide therapy as a potential alternative or complement to the traditional theranostic approach with iodine-123 (123I)/iodine-131 (131I)-labelled meta-iodobenzylguanidine. Genomic characterisation of subgroups with differing risk of lesion development and subsequent metastatic spread is refining the use of molecular imaging in the personalised approach to hereditary PPGL patients for detection, staging, and follow-up surveillance
- …
